1 Market Overview
1.1 Product Overview and Scope of Age-Related Macular Degeneration (AMD) Therapeutics
1.2 Classification of Age-Related Macular Degeneration (AMD) Therapeutics by Type
1.2.1 Overview: Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type: 2021 Vs 2022 Vs 2027 Vs 2030
1.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type in 2022
1.2.3 Wet AMD
1.2.4 Dry AMD
1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
1.3.1 Overview: Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application: 2021 Vs 2022 Vs 2027 Vs 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Other
1.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size & Forecast
1.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast by Region
1.5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region, (2018-2022)
1.5.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2030)
1.5.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2030)
1.5.5 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2030)
1.5.6 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2030)
1.5.7 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Prospect (2018-2030)
1.6 Market Drivers, Restraints and Trends
1.6.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
1.6.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
1.6.3 Age-Related Macular Degeneration (AMD) Therapeutics Trends Analysis
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Amgen Inc. Details
2.1.2 Amgen Inc. Major Business
2.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.1.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Amgen Inc. Recent Developments and Future Plans
2.2 Bausch Health Companies, Inc.
2.2.1 Bausch Health Companies, Inc. Details
2.2.2 Bausch Health Companies, Inc. Major Business
2.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.2.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bausch Health Companies, Inc. Recent Developments and Future Plans
2.3 F. Hoffmann-La Roche Ltd.
2.3.1 F. Hoffmann-La Roche Ltd. Details
2.3.2 F. Hoffmann-La Roche Ltd. Major Business
2.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.3.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.4 Novartis AG
2.4.1 Novartis AG Details
2.4.2 Novartis AG Major Business
2.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.4.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis AG Recent Developments and Future Plans
2.5 Regeneron Pharmaceuticals Inc.
2.5.1 Regeneron Pharmaceuticals Inc. Details
2.5.2 Regeneron Pharmaceuticals Inc. Major Business
2.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
2.5.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Regeneron Pharmaceuticals Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share
3.2.2 Top 10 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Age-Related Macular Degeneration (AMD) Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Market Share by Type (2018-2022)
4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2018-2022)
5.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2030)
6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2030)
6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
6.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2030)
6.3.2 United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
6.3.3 Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
6.3.4 Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
7 Europe by Country, by Type, and by Application
7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2030)
7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2030)
7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
7.3.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2030)
7.3.2 Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
7.3.3 France Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
7.3.4 United Kingdom Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
7.3.5 Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
7.3.6 Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2030)
8.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2030)
8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region
8.3.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018-2030)
8.3.2 China Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
8.3.3 Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
8.3.4 South Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
8.3.5 India Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
8.3.6 Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
8.3.7 Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
9 South America by Country, by Type, and by Application
9.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2030)
9.2 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2030)
9.3 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
9.3.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2030)
9.3.2 Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
9.3.3 Argentina Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2030)
10.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2030)
10.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
10.3.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2030)
10.3.2 Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
10.3.3 Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
10.3.4 UAE Age-Related Macular Degeneration (AMD) Therapeutics Market Size and Forecast (2018-2030)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Age-Related Macular Degeneration (AMD) Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) by Region (2018-2022)
Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Amgen Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Amgen Inc. Major Business
Table 8. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 9. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bausch Health Companies, Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Bausch Health Companies, Inc. Major Business
Table 12. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 13. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 15. F. Hoffmann-La Roche Ltd. Major Business
Table 16. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 17. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 19. Novartis AG Major Business
Table 20. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 21. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Regeneron Pharmaceuticals Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Regeneron Pharmaceuticals Inc. Major Business
Table 24. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product and Solutions
Table 25. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Players (2019-2021)
Table 28. Breakdown of Age-Related Macular Degeneration (AMD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 29. Age-Related Macular Degeneration (AMD) Therapeutics Players Head Office, Products and Services Provided
Table 30. Age-Related Macular Degeneration (AMD) Therapeutics Mergers & Acquisitions in the Past Five Years
Table 31. Age-Related Macular Degeneration (AMD) Therapeutics New Entrants and Expansion Plans
Table 32. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) by Type (2018-2022)
Table 33. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type (2018-2022)
Table 34. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Forecast by Type (2021-2026)
Table 35. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2022)
Table 36. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Forecast by Application (2021-2026)
Table 37. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2022) & (USD Million)
Table 38. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 39. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2022) & (USD Million)
Table 40. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 41. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2022) & (USD Million)
Table 42. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 43. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2022) & (USD Million)
Table 44. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 45. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2022) & (USD Million)
Table 46. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 47. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2022) & (USD Million)
Table 48. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 49. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2022) & (USD Million)
Table 50. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 51. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2022) & (USD Million)
Table 52. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 53. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2018-2022) & (USD Million)
Table 54. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 55. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2022) & (USD Million)
Table 56. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 57. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2022) & (USD Million)
Table 58. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 59. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2022) & (USD Million)
Table 60. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 61. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2018-2022) & (USD Million)
Table 62. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 63. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2018-2022) & (USD Million)
Table 64. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 65. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2018-2022) & (USD Million)
Table 66. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Age-Related Macular Degeneration (AMD) Therapeutics Picture
Figure 2. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type in 2022
Figure 3. Wet AMD
Figure 4. Dry AMD
Figure 5. Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application in 2020
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Research Institute Picture
Figure 9. Other Picture
Figure 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Forecast (2018-2030) & (USD Million)
Figure 12. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2018-2030)
Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) and Growth Rate (2018-2030)
Figure 15. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) and Growth Rate (2018-2030)
Figure 16. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) and Growth Rate (2018-2030)
Figure 17. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) and Growth Rate (2018-2030)
Figure 18. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue (USD Million) and Growth Rate (2018-2030)
Figure 19. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
Figure 20. Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
Figure 21. Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
Figure 22. Amgen Inc. Recent Developments and Future Plans
Figure 23. Bausch Health Companies, Inc. Recent Developments and Future Plans
Figure 24. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 25. Novartis AG Recent Developments and Future Plans
Figure 26. Regeneron Pharmaceuticals Inc. Recent Developments and Future Plans
Figure 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Players in 2020
Figure 28. Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 29. Global Top 3 Players Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share in 2020
Figure 30. Global Top 10 Players Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share in 2020
Figure 31. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 32. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Type in 2022
Figure 33. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share Forecast by Type (2021-2026)
Figure 34. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Share by Application in 2020
Figure 35. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share Forecast by Application (2021-2026)
Figure 36. North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Type (2018-2030)
Figure 37. North America Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Application (2018-2030)
Figure 38. North America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Country (2018-2030)
Figure 39. United States Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 40. Canada Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 41. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 42. Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Type (2018-2030)
Figure 43. Europe Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Application (2018-2030)
Figure 44. Europe Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Country (2018-2030)
Figure 45. Germany Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 46. France Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 47. United Kingdom Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 48. Russia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 49. Italy Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 50. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Type (2018-2030)
Figure 51. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Application (2018-2030)
Figure 52. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Region (2018-2030)
Figure 53. China Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 54. Japan Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 55. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 56. India Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 57. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 58. Australia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 59. South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Type (2018-2030)
Figure 60. South America Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Application (2018-2030)
Figure 61. South America Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Country (2018-2030)
Figure 62. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 63. Argentina Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 64. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Type (2018-2030)
Figure 65. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Sales Market Share by Application (2018-2030)
Figure 66. Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Country (2018-2030)
Figure 67. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 68. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 69. UAE Age-Related Macular Degeneration (AMD) Therapeutics Revenue and Growth Rate (2018-2030) & (USD Million)
Figure 70. Methodology
Figure 71. Research Process and Data Source
